Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S132000
Reexamination Certificate
active
07141592
ABSTRACT:
The present invention relates generally to substituted oxadiazolidinediones and methods of using them.
REFERENCES:
patent: 3026325 (1962-03-01), Heinzelman et al.
patent: 3476770 (1969-11-01), Scherrer
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4478819 (1984-10-01), Hercelin et al.
patent: 4736043 (1988-04-01), Michel et al.
patent: 4851406 (1989-07-01), Martens et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5420146 (1995-05-01), Malamas et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5468762 (1995-11-01), Malamas et al.
patent: 5480896 (1996-01-01), Malamas et al.
patent: 5482960 (1996-01-01), Berryman
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5532256 (1996-07-01), Malamas et al.
patent: 5541343 (1996-07-01), Himmelsbach et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6251936 (2001-06-01), Wrobel et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6479524 (2002-11-01), Priepke et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 2003/0013732 (2003-01-01), Elokdah
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0060497 (2003-03-01), Gerlach et al.
patent: 2003/0125371 (2003-07-01), Elokdah et al.
patent: 2004/0116488 (2004-06-01), Jennings et al.
patent: 2004/0116504 (2004-06-01), Elokdah et al.
patent: 2004/0122070 (2004-06-01), Jennings
patent: 2004/0138283 (2004-07-01), Jennings et al.
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 2005/0070584 (2005-03-01), Havran et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: 2005/0070592 (2005-03-01), Gundersen
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0113428 (2005-05-01), Gopalsamy et al.
patent: 2005/0113436 (2005-05-01), Elokdah et al.
patent: 2005/0113438 (2005-05-01), Hu et al.
patent: 2005/0113439 (2005-05-01), Hu
patent: 2005/0119296 (2005-06-01), Elokdah et al.
patent: 2005/0119326 (2005-06-01), Havran et al.
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0215626 (2005-09-01), Havran et al.
patent: 2006/0020003 (2006-01-01), Commons et al.
patent: 2006/0052348 (2006-03-01), Commons et al.
patent: 2006/0052349 (2006-03-01), Commons et al.
patent: 2006/0052420 (2006-03-01), Commons
patent: 3147276 (1983-06-01), None
patent: 43 38 770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 759 434 (1997-02-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 822 185 (1998-02-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1 156 045 (2001-11-01), None
patent: 2 244 499 (1975-04-01), None
patent: 2 777 886 (1999-10-01), None
patent: 2 799 756 (2001-04-01), None
patent: 1 321 433 (1973-06-01), None
patent: 94/13637 (1994-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: WO 9425448 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: 00/46195 (2000-08-01), None
patent: 00/46197 (2000-08-01), None
patent: 00/64876 (2000-11-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/12187 (2001-02-01), None
patent: 02/030895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
Gopalsamy, A. et al., “Design and synthesis of oxadizolidinediones as inhibitors of plasminogen activator inhibitor-1,”Bioorganic&Medicinal Chemistry Letters, 2004, 14:3477-3480.
U.S. Appl. No. 10/947,856, filed Sep. 23, 2004, Elokdah et al.
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood, 69(3): 798-803 (Mar. 1987).
Reilly, C. et al., “Both Circulating and Clot-Bound Plasminogen Activator-1 Inhibit Endogenous Fibrinolysis in the Rat,”Arteriosclerosis and Thrombosis, 11(5): 1276-1286 (Sep./Oct. 1991).
Carmeliet, P. et al., “Plasminogen Activator Inhibitor-1 Gene-deficient Mice,”Journal of Clinical Investigation, 92: 2756-2760 (Dec. 1993).
Rocha, E. et al., “The Relationship Between Impaired Fibrinolysis and Coronary Heart Disease,”Fibrinolysis, 8: 294-303 (1994).
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis24: 243-251 (1994).
Biemond, B. J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation, 91: 1175-1181 (1995).
Levi, M. et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Experimental Thrombosis,”Circulation85:305-312 (1992).
Nordt, T. K. et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells,”Journal of Clinical Endocrinology and Metabolism, 85(4):1563-1568 (2000).
Daci, E. et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone and Mineral Research, 15(8):1510-1516 (Nov. 8, 2000).
Schneiderman J. et. al., “Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries,”Proc Natl Acad Sci89: 6998-7002 (Aug. 1992).
Juhan-Vague, I. et. al., “Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis,”Thromb Haemost57: 67-72 (1987).
Juhan-Vague, I. et. al., “PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events,”Thromb Haemost78: 565-660 (1997).
Hamsten, A. et. al., “Plasminogen Activator Inhibitor in Plasma: Risk Factor For Recurrent Myocardial Infarction,”Lancet2: 3-9 (Jul. 4, 1987).
Siemens, H. J. et. al., “Course of Molecular Hemostatic Markers During and After Different Surgical Procedures,”J Clin Anesthesia11: 622-629 (Dec. 1999).
Koh, K. et. al., “Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women,”N Engl J Med336(10): 683-690 (Mar. 6, 1997).
Malamas, M. S. et al., “New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties,”J. Med. Chem., 2000, 43:995-1010.
Malamas, M. S. et al., “Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones,”Eur. J. Med. Chem., 2001, 36:31-42.
U.S. Appl. No. 10/947,711, filed Sep. 23, 2004, Gopalsamy et al.
Aggarwal et al., “A catalytic antibody programmed for torsional activation of amide bond hydrolysis, ”Chem. Eur. J.,Jan. 25, 2003, 9(13), 3132-3142.
Ballantine, J.A., “The Chemistry of Bacteria,”Journal of
Gopalsamy Ariamala
Kincaid Scott Lee
Barker Michael
Saeed Kamal A.
Woodcock & Washburn LLP
Wyeth
LandOfFree
Substituted oxadiazolidinediones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted oxadiazolidinediones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted oxadiazolidinediones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634603